#elispot

[axispharm]

Difference Between ELISPOT and ELISA

Difference Between ELISPOT and ELISA

October 18, 2022 Posted by Axispharm

With the wide application of ELISA technology in the medical and biological fields, new breakthroughs have been made in the detection of various cytokines and antibodies in vitro. When studying the mechanism of immune response, enzyme-linked immunosorbent assay (ELISA) was used to detect free cytokines (CK) or antibodies in body fluids. Metabolized or combined with target organs, but cannot accurately reflect the level of antibodies and CK in vivo. In the 1980s, based on the basic principle of ELISA technology, researchers established a solid-phase enzyme-linked immunospot technique (ELISPOT) for detecting specific antibody-secreting cells and CK-secreting cells in vitro.

Main difference between ELISPOT and ELISA:

The ELISPOT method is derived from ELISA and breaks through the traditional ELISA method. It is an extension and new development of quantitative ELISA technology. Both detect cytokines or other soluble proteins produced by cells, and their biggest differences are:

1. ELISA measures the absorbance on a microplate reader through a color reaction, and compares it with the standard curve to obtain a quantitative total amount of soluble protein.

2. ELISPOT shows clearly distinguishable spots on the corresponding positions where the soluble protein is secreted by cells through the color reaction. The spots can be manually counted directly under the microscope or counted by the ELISPOT analysis system. One spot represents one spot. Active cells to calculate the frequency of cells secreting the protein or cytokine. (Some studies measure not only the amount of cytokine produced, but also the frequency of cells secreting the cytokine)

3. Because it is a single-cell level detection, ELISPOT is more sensitive than ELISA and limiting dilution methods, and can detect 1 cell secreting this protein from 200,000-300,000 cells.

4. The capture antibody is a high-affinity, high-specificity, low-endotoxin monoclonal antibody produced by Swedish high-tech biological company MABTECH, BD, R&D. When researchers activate cells with stimulators, they will not affect the secretion of cytokines by activated cells.

Detection principle

Cells are stimulated to locally produce cytokines, which are captured by specific monoclonal antibodies. After cell dissociation, the captured cytokines bind to biotin-labeled secondary antibodies, which in turn bind to alkaline phosphatase-labeled avidin. After incubation with BCIP/NBT substrate, “purple” spots appeared on the PVDF plate, indicating that the cells produced cytokines, and the results were obtained after the spots were analyzed by the ELISPOT enzyme-linked spot analysis system.

Application field

Prediction of rejection in transplantation, vaccine development, Th1/Th2 analysis, autoimmune disease research, tumor research, allergic disease research, infectious disease research, epitope mapping analysis, screening of compounds and drug immunological responses, etc.

[aimarketresearch]

Immunodiagnostics Market Size, Share, Trends, Demand, Growth, Challenges and Competitive Analysis

Executive Summary Immunodiagnostics Market :

Data Bridge Market Research analyses that the Immunodiagnostics market which was USD 16.87 Billion in 2022, would rocket up to USD 36.54 Billion by 2030, and is expected to undergo a CAGR of 12.8% during the forecast period.

This Immunodiagnostics Market business report is an analytical consideration of the prime challenges that may arrive in the market in terms of sales, export, import, or revenue. This market report is a comprehensive analysis on the study of  industry that gives number of market insights. This market research report describes the major moves of the top players and brands such as developments, product launches, acquisitions, mergers, joint ventures and competitive research in the market. It is a professional and in-depth analysis on the current state of the market. Immunodiagnostics Market report aids to focus on the significant aspects of the market like what the recent market trends are or what buying patterns of the consumers are.

Global Immunodiagnostics Market report conducts thorough competitive research to provide better market insights. This market report performs comprehensive study about  industry and tells about the market status in the forecast period. The report explains the moves of top market players and brands that range from developments, products launches, acquisitions, mergers, joint ventures, trending innovation and business policies. This market analysis examines various segments which aids for the quickest development amid the estimated forecast frame. Geographical areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa are also considered for the market analysis.

Discover the latest trends, growth opportunities, and strategic insights in our comprehensive Immunodiagnostics Market report. Download Full Report: https://www.databridgemarketresearch.com/reports/global-immunodiagnostics-market

Immunodiagnostics Market Overview

**Segments**

- By Product (Reagents, Instruments, Software & Services) - By Technology (Enzyme-Linked Immunosorbent Assay, Chemiluminescence Immunoassay, Radioimmunoassay, Fluorescent Immunoassay, Protein Microarray, Rapid Test, Western Blot, ELISpot, PCR) - By Application (Oncology & Endocrinology, Hepatitis & Retrovirus Testing, Infectious Disease Testing, Autoimmune Testing, Bone & Mineral Disorders Testing, Allergy Testing) - By End-User (Hospitals, Clinical Laboratories, Blood Banks, Academic Research Centers, Pharmaceutical Companies, Contract Research Organizations)

The global immunodiagnostics market is segmented based on product type, technology, application, and end-user. In terms of products, the market is categorized into reagents, instruments, and software & services. The technology segment includes enzyme-linked immunosorbent assay, chemiluminescence immunoassay, radioimmunoassay, fluorescent immunoassay, protein microarray, rapid test, western blot, ELISpot, and PCR. Immunodiagnostics find applications in various fields such as oncology & endocrinology, hepatitis & retrovirus testing, infectious disease testing, autoimmune testing, bone & mineral disorders testing, and allergy testing. End-users of immunodiagnostics include hospitals, clinical laboratories, blood banks, academic research centers, pharmaceutical companies, and contract research organizations.

**Market Players**

- F. Hoffmann-La Roche Ltd - Siemens Healthineers - Abbott - Danaher - DiaSorin S.p.A - Ortho Clinical Diagnostics - QIAGEN - Thermo Fisher Scientific Inc - Bio-Rad Laboratories, Inc. - Sysmex Corporation - bioMérieux SA

Key players in the global immunodiagnostics market include F. Hoffmann-La Roche Ltd, Siemens Healthineers, Abbott, Danaher, DiaSorin S.p.A, Ortho Clinical Diagnostics, QIAGEN, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Inc., Sysmex Corporation, and bioMérieux SA. These companies are actively involved in research and development activities to introduce innovative immunodiagnostic products in the market. The competitive landscape of the market is characterized by strategic collaborations, mergers & acquisitions, and product launches to strengthen their market presence and expand their product portfolios.

The global immunodiagnostics market is experiencing significant growth driven by factors such as increasing prevalence of infectious diseases, rising demand for personalized medicine, advancements in technology, and growing awareness about early disease detection. The market is witnessing a shift towards more accurate and efficient diagnostic tools to aid in precise disease diagnosis and monitoring. With the emergence of innovative technologies and the development of targeted therapies, the demand for immunodiagnostics is expected to rise in the coming years.

One of the key trends shaping the immunodiagnostics market is the growing adoption of point-of-care testing. This trend is driven by the need for rapid and accurate diagnostic results, especially in emergency situations or remote settings. Point-of-care testing offers quick turnaround times and enables healthcare providers to make immediate treatment decisions, resulting in improved patient outcomes. Key players in the market are focusing on developing portable and user-friendly point-of-care immunodiagnostics devices to cater to the increasing demand for decentralized testing.

Another trend in the immunodiagnostics market is the integration of artificial intelligence (AI) and machine learning technologies. These advanced technologies are being utilized to enhance the accuracy and efficiency of diagnostic tests, reduce human errors, and streamline data analysis processes. AI algorithms can analyze large volumes of patient data to identify patterns and trends that may not be apparent to human analysts. By leveraging AI and machine learning, healthcare providers can improve diagnostic accuracy, speed up decision-making, and optimize treatment pathways for better patient care.

Moreover, the COVID-19 pandemic has further accelerated the adoption of immunodiagnostics technology. The need for rapid and reliable diagnostic tests for SARS-CoV-2 has highlighted the importance of immunodiagnostics in infectious disease testing. Market players have swiftly developed and launched new immunodiagnostic products specifically designed for COVID-19 screening, diagnosis, and monitoring. This rapid response has showcased the agility and innovation within the industry to address emerging healthcare challenges.

Looking ahead, the global immunodiagnostics market is poised for continued growth, fueled by ongoing technological advancements, increasing investments in research and development, and the rising demand for accurate and personalized diagnostics. Market players will continue to focus on product innovation, strategic collaborations, and geographic expansion to strengthen their market position and meet the evolving needs of healthcare providers and patients globally. As the demand for precision medicine and personalized healthcare grows, immunodiagnostics will play a crucial role in shaping the future of diagnostics and disease management.The global immunodiagnostics market is a dynamic and rapidly evolving sector driven by the increasing prevalence of infectious diseases, advancements in technology, and the rising demand for personalized medicine. Key market players such as F. Hoffmann-La Roche Ltd, Siemens Healthineers, and Abbott are actively engaged in research and development efforts to introduce innovative immunodiagnostic products and maintain their competitive edge in the market. The market landscape is characterized by strategic collaborations, mergers & acquisitions, and product launches to expand product portfolios and enhance market presence.

One of the notable trends shaping the immunodiagnostics market is the growing adoption of point-of-care testing. This trend is fueled by the need for rapid and accurate diagnostic results, especially in emergency or remote settings, leading to improved patient outcomes. Key market players are focusing on developing portable and user-friendly point-of-care immunodiagnostics devices to cater to the increasing demand for decentralized testing, providing healthcare providers with immediate treatment decision-making capabilities.

Another significant trend in the immunodiagnostics market is the integration of artificial intelligence (AI) and machine learning technologies. These advanced technologies are being employed to enhance diagnostic test accuracy, reduce human errors, and streamline data analysis processes, ultimately improving patient care outcomes. AI algorithms can analyze vast amounts of patient data to identify patterns and trends, aiding healthcare providers in making informed decisions and optimizing treatment pathways effectively.

The COVID-19 pandemic has further accelerated the adoption and development of immunodiagnostics technology. The urgent need for rapid and reliable diagnostic tests for SARS-CoV-2 has underscored the critical role of immunodiagnostics in infectious disease testing. Market players have swiftly responded by developing and launching new immunodiagnostic products tailored for COVID-19 screening, diagnosis, and monitoring, showcasing the industry's agility and innovation in addressing emerging healthcare challenges.

Looking ahead, the global immunodiagnostics market is poised for sustained growth driven by ongoing technological advancements, increased investments in research and development, and the escalating demand for accurate and personalized diagnostics. Market players will continue to prioritize product innovation, strategic partnerships, and geographical expansion to strengthen their market position and meet the evolving needs of healthcare providers and patients worldwide. As precision medicine and personalized healthcare gain momentum, immunodiagnostics will continue to play a pivotal role in shaping the future of diagnostics and disease management, offering new insights on market dynamics, trends, and opportunities.

The Immunodiagnostics Market is highly fragmented, featuring intense competition among both global and regional players striving for market share. To explore how global trends are shaping the future of the top 10 companies in the keyword market.

Learn More Now: https://www.databridgemarketresearch.com/reports/global-immunodiagnostics-market/companies

DBMR Nucleus: Powering Insights, Strategy & Growth

DBMR Nucleus is a dynamic, AI-powered business intelligence platform designed to revolutionize the way organizations access and interpret market data. Developed by Data Bridge Market Research, Nucleus integrates cutting-edge analytics with intuitive dashboards to deliver real-time insights across industries. From tracking market trends and competitive landscapes to uncovering growth opportunities, the platform enables strategic decision-making backed by data-driven evidence. Whether you're a startup or an enterprise, DBMR Nucleus equips you with the tools to stay ahead of the curve and fuel long-term success.

How Immunodiagnostics Market Report Would Be Beneficial?

Anyone who are directly or indirectly connected in value chain of Immunodiagnostics Market industry and needs to have Know-How of market trends

Marketers and agencies doing their due diligence

Analysts and vendors looking for Immunodiagnostics Market intelligence about Immunodiagnostics Market Industry

Competition who would like to correlate and benchmark themselves with market position and standings in current scenario

Browse More Reports:

Global Offshore Mooring Systems Market Global Industrial Backhoe Loader Market Global Hybrid and Community Cloud as a Service Market North America Stand-Up Paddleboard Market Global Eggshell Membrane Powder Market Global Aluminium Composite Panels Market Global Bulk Chemical Drums Market Asia-Pacific Pharmaceuticals Packaging Testing Equipment Market Global Composite Materials Market Global Semi-Finished Pastry Ingredients Market Global Fragrance Packaging Market Global Electrical Discharge Machine (EDM) Market Global Bio-Based Polypropylene (PP) Market Global Flat Back Tape Market Global 3D Laser Scanner Market North America Freight Transportation Management Market Asia-Pacific API Intermediates Market North America Defibrillators Market Asia-Pacific Smoked Cheese Market Europe Soft Tissue Repair Market Global Crambe Abyssinica Seed Oil Market Europe Anthrax Treatment Market Global Dog Food Extrusion Market Global Waterproof Coatings and Membranes Market Australia and New Zealand Non-Stick Cookware Market Global Cerebral Palsy Market Global Snow Pushers Market Global Electro Pneumatic Train Brakes Market Global Loyalty Management Market Global Connected Living Room Market Global Specialty Oilfield Chemicals Market Global Botanical Ingredients for Neutraceutical Market Global Residential Portable Air Purifier Market North America Chinese Hamster Ovary (CHO) Cells Market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us: Data Bridge Market Research US: +1 614 591 3140 UK: +44 845 154 9652 APAC : +653 1251 975 Email:- corporatesales@databridgemarketresearch.com

Tag:- Immunodiagnostics Market, Immunodiagnostics Market Trends, Immunodiagnostics Market Growth, Immunodiagnostics Market Demand, Immunodiagnostics Market Size, Immunodiagnostics Market Scope, Immunodiagnostics Market Insights, Immunodiagnostics Market Analysis

[vishvajit123]

ELISpot and FluoroSpot Assay Market by Product Type Featuring Global Market Size, Segment-Wise Analysis, Regional Landscape, Company Share Evaluation, Key Player Profiles, and Forecast from 2025 to 2035

Industry Outlook for the ELISpot and FluoroSpot Assay Market

The ELISpot and FluoroSpot Assay market was valued at USD 318.4 million in 2024 and is projected to reach USD 705.45 million by 2035, growing at a CAGR of approximately 7.5% from 2025 to 2035. These assays are widely used in laboratory settings to detect and quantify cellular protein secretions at the individual cell level. ELISpot (Enzyme-Linked ImmunoSpot) and FluoroSpot assays are essential in immunological and biomedical research for evaluating immune responses, particularly by detecting cytokine-producing cells.

ELISpot utilizes enzymatic colorimetric analysis, while FluoroSpot detects multiple analytes through fluorescent dyes. Their high sensitivity, reproducibility, and precision make them indispensable in vaccine development, cancer immunotherapy, infectious disease diagnostics, and autoimmune research. The growth of this market is primarily driven by the advancement of immunotherapies and the increasing demand for personalized medicine.

Get free sample Research Report - https://www.metatechinsights.com/request-sample/2174

Rising Demand for Immunotherapy Fuels Assay Market Growth

The widespread adoption of immunotherapy for treating cancer, autoimmune diseases, and infectious conditions is a major catalyst for the ELISpot and FluoroSpot assay market. These assays are vital in tracking the effectiveness of immune-based therapies by measuring the secretion of cytokines at the cellular level. As clinical trials for immunotherapies and vaccines increase globally, so does the demand for sensitive and accurate immune monitoring tools.

The market is further bolstered by heightened investment in personalized medicine, where tailored immunological responses are essential. This growing medical focus ensures sustained demand for ELISpot and FluoroSpot assay kits and instruments.

Prevalence of Infectious and Autoimmune Diseases Drives Market Expansion

The increasing incidence of infectious diseases like HIV, tuberculosis, hepatitis, and COVID-19, alongside autoimmune disorders such as rheumatoid arthritis, lupus, and multiple sclerosis, is significantly expanding the market for ELISpot and FluoroSpot assays. These tools allow for early and accurate diagnosis and are critical in evaluating treatment efficacy.

As healthcare systems worldwide strive for faster and more precise diagnostic capabilities, ELISpot and FluoroSpot technologies are being adopted widely. Additionally, global health awareness campaigns and disease control initiatives are accelerating the demand for advanced immune-monitoring assays.

High Cost of Kits and Equipment Poses a Market Restraint

Despite their advantages, the high costs of assay kits and instruments remain a significant barrier to market penetration, particularly in developing nations. Specialized instruments require a substantial upfront investment and regular maintenance, making them less accessible to small labs and institutions with limited budgets.

Operational costs are further increased due to calibration and upkeep. Cost-sensitive markets often seek more affordable alternatives, slowing the widespread adoption of ELISpot and FluoroSpot assays. To overcome this hurdle, manufacturers are focusing on developing cost-effective solutions and establishing collaborative distribution strategies.

Emerging Markets Offer Promising Growth Potential

The rapid expansion of healthcare infrastructure and research funding in emerging markets such as Asia-Pacific, Latin America, and the Middle East presents lucrative growth opportunities for the ELISpot and FluoroSpot assay market. These regions are seeing increased prevalence of infectious and autoimmune diseases, driving demand for advanced diagnostic tools.

Pharmaceutical and biotech companies are investing heavily in these regions, aided by improved regulatory frameworks and the availability of skilled professionals. To succeed in these markets, companies are forming local partnerships and developing region-specific, affordable product offerings.

Technological Integration with Automation and AI Enhancing Market Efficiency

The integration of automation and digital technologies with ELISpot and FluoroSpot assays is transforming the landscape of immune diagnostics. Automation improves the speed, accuracy, and efficiency of assay procedures, making these platforms suitable for high-throughput laboratories and clinical applications.

AI-powered image recognition and digital analysis tools enhance spot detection accuracy, streamlining data interpretation. These tech-driven advancements are especially beneficial in vaccine development and immunotherapy research, where precision is crucial. The growing adoption of digital health solutions is expected to significantly boost market expansion in the coming years.

Expert Insight on Market Growth

"The growing prevalence of infectious and autoimmune diseases is pushing the demand for highly sensitive immune monitoring assays, creating significant opportunities in emerging markets."

– Dr. Rajesh Gupta, Chief Scientific Officer, Global ImmunoDiagnostics

Product Type Analysis: Assay Kits Lead the Market

In terms of product type, assay kits hold the largest share in the ELISpot and FluoroSpot assay market. These kits are preferred for their high sensitivity and ease of use in detecting cytokine-secreting cells. ELISpot assay kits are particularly dominant in pharmaceutical research, vaccine development, and immunotherapy studies.

Technological advancements in assay kit design and a rise in clinical trials have further contributed to the growth of this segment. Researchers favor these kits due to their reliability, cost-effectiveness, and consistent results in immune profiling.

Read Full Research Report https://www.metatechinsights.com/industry-insights/elispot-and-fluorospot-assay-market-2174

Application Insights: Vaccine Development Dominates

Vaccine development is currently the leading application segment for ELISpot and FluoroSpot assays. These assays play a critical role in evaluating immune responses to vaccines by measuring T-cell activation against specific antigens. Their usage increased significantly during the COVID-19 pandemic and continues to rise with research into vaccines for HIV, tuberculosis, and other infectious diseases.

The growing number of government-funded vaccine projects and private sector initiatives supports the segment's continued dominance. ELISpot and FluoroSpot assays are also pivotal in understanding long-term immunity and optimizing vaccine design.

Regional Overview: North America Leads, Asia Pacific on the Rise

North America remains the leading region in the ELISpot and FluoroSpot assay market due to its advanced healthcare infrastructure, active pharmaceutical R&D, and high disease burden. The United States drives regional growth through strong government support, widespread clinical trials, and adoption of cutting-edge diagnostic technologies.

Asia Pacific is experiencing rapid market growth fueled by increased healthcare spending and the expansion of biotech industries in China, India, and Japan. The rising prevalence of infectious diseases and autoimmune disorders, combined with supportive government policies, is boosting demand for advanced immunological assays in the region.

Competitive Landscape and Key Players

The ELISpot and FluoroSpot assay market is highly competitive, with leading players focusing on innovation, global expansion, and strategic collaborations. Key companies include Oxford Immunotec USA, Inc., Cellular Technology Limited, Mabtech AB, U-CyTech Biosciences, and Autoimmun Diagnostika GmbH. These firms offer comprehensive assay kits, analyzers, and related services.

Industry leaders are investing in product innovation to enhance assay sensitivity, automation capabilities, and digital integration. Mabtech AB’s new FluoroSpot analyzers and Oxford Immunotec’s pharmaceutical partnerships for vaccine development are notable developments. The increasing adoption of digital tools and personalized medicine approaches continues to shape the market's competitive dynamics.

Buy Now https://www.metatechinsights.com/checkout/2174

Recent Developments in the ELISpot and FluoroSpot Assay Market

In September 2024, a report by BlueWeave Consulting projected significant market growth for ELISpot and FluoroSpot assays driven by rising demand for sensitive immune assays and biotechnology advancements.

In September 2023, Virax Biolabs Group Limited launched early access to its SARS-CoV-2 ViraxImmune T-cell-based test. This innovative diagnostic tool uses a peptide pool along with a pre-coated ELISpot assay to evaluate memory T-cell activation specific to SARS-CoV-2.

[blueweave]

 ELISpot and FluoroSpot Assay Market size at USD 289.80 million in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global ELISpot and FluoroSpot Assay Market size to expand at a CAGR of 7.60% reaching a value of USD 479.50 million by 2030. Several factors contribute to the market growth, including the rising prevalence of chronic diseases, the emergence of new infectious diseases, and the growing demand for vaccines to prevent infectious diseases. Companies' technological advancements are also expected to drive Global ELISpot and FluoroSpot Assays Market over the forecast period.

Sample Request @ https://www.blueweaveconsulting.com/report/elispot-and-fluorospot-assay-market/report-sample

Opportunity - Increasing Prevalence of Infectious Diseases

The rising prevalence of various infectious diseases, such as malaria, leishmaniasis, and HIV-AIDS, globally is directly propelling the demand for ELISpot and fluoroSport assays. Cancer also covers a significant market share owing to the growing burden of cancer worldwide and the rising need for its early detection.

[naveendsw]

ELISpot And Fluorospot Assay Market Size, Share & Report 2030

[sudheervanguri]

Sun pharma baroda recruitment notification Sun Pharma, a global leader in pharmaceuticals, is currently hiring for the position of R&D Biotechnology - Immunogenicity Executive at their Baroda location. This role requires a candidate with 2-4 years of experience in immunogenicity assays and a strong background in biotechnology. If you have the necessary qualifications and are eager to contribute to innovative research, this opportunity is perfect for you. Job Details: Job Title: R&D Biotechnology - Immunogenicity Executive Experience: 2-4 years Grade: Executive Location: Baroda, India Key Role: As an R&D Biotechnology - Immunogenicity Executive, you will be responsible for developing multiplex-based cytokine release assays and ELISPOT/flow cytometry-based T cell assays. These assays are critical for measuring the innate and adaptive immunogenicity of synthetic peptide products. Job Responsibilities: Development of multiplex based cytokine release assay and Elispot/ flow cytometry based T cell assays to measure the innate and adaptive Immunogenicity of synthetic peptide products Job Responsibilities: Responsible for study sample analysis for all pipeline products.  Isolation of PBMC from whole blood and maintenance of commercial cell lines.   Data compilation, QC & Statistical analysis of data.  Preparation of standard operating procedures (SOP), method development reports (MDR) and analytical test procedures (ATP). Responsible for operating and maintaining analytical laboratory in compliance with GLP regulations. Responsible for the operation and maintenance of the Flow Cytometry, Multiplex, ELISPOT and other instruments. Management of chemicals, consumables & critical reagents inventory. Performing calibration of instruments and equipment. Troubleshooting instrument performance and equipment issues. Qualifications: Education: Degree in Biotechnology or related field. Experience: 2-4 years in a relevant role, specifically in immunogenicity assays. Skills: Proficiency in flow cytometry, ELISPOT, and cytokine release assays. Strong analytical and statistical analysis skills. Compliance: Knowledge of GLP regulations and experience in maintaining compliance in a laboratory setting. How to Apply: Interested candidates are encouraged to send their resume and cover letter to Rosemary Varghese at Rosemary.varghese@sunpharma.com with the subject line "R&D Biotechnology - Immunogenicity Executive Application". [caption id="attachment_56281" align="aligncenter" width="930"] Sun Pharmaceutical Industries recruitment notification[/caption]